Byoung Chul Cho, MD, PhD, from Yonsei University, discusses the Phase II AdvanTIG-202 (NCT04693234) trial, evaluating tislelizumab, an anti-PD-1 monoclonal antibody (mAb), with or without ociperlimab, an anti-TIGIT mAb, in previously treated recurrent or metastatic cervical cancer (R/M CC). In the primary analysis of 138 enrolled patients, the tislelizumab plus ociperlimab combination demonstrated an overall response rate (ORR) of 22.5%, including 13 complete responses, with 76.8% showing a durable response of ≥6 months. Notably, PD-L1-positive tumors exhibited an ORR of 26.2%. Both analysis sets revealed a significant improvement in ORR compared to historical controls with anti-PD-1 therapy. Approximately 67% of patients experienced treatment-related adverse events, with only 13% being ≥grade 3. Limited enrollment in the tislelizumab monotherapy cohort showed an ORR of 32.5%. This promising antitumor activity and tolerability suggest a potential benefit in previously treated R/M CC. This interview occurred at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
